An alpha turnaround for Relay
The fortunes of RLY-2608 reverse, and a pivotal study will follow.
The fortunes of RLY-2608 reverse, and a pivotal study will follow.
Akeso’s data look impressive, but perhaps not impressive enough to sustain Summit’s valuation.
The mid-stage Ideate-Lung01 study bears out ifinatamab-dxd’s efficacy in small-cell lung cancer.
The depressed company could use Mylotarg as a stepping stone in AML.
An accelerated approval looks off the table, as the group’s first-line melanoma trial continues.
It’s back to school for biotech, with a packed conference schedule.